Biotech RadarJobs updated

COMPANY

Secura Bio

HQ: San Diego, CA source · securabio.com ↗

Status: Acquired, now part of Athyrium Capital Management · How status works

Clinical Phase 3

5 open jobs · last seen Oct 23, 2026 · 25 sources

Location: San Diego, CA · source · Apr 1, 2019

Profile checked Oct 10, 2026

Keywords: Lymphoma Follicular Lymphoma Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Indolent Non-Hodgkin Lymphoma Mycosis Fungoides Cutaneous T-cell Lymphoma Peripheral T-cell Lymphoma CD20+ Follicular Lymphoma Head and Neck Squamous Cell Carcinoma Hematologic Malignancy Non-Hodgkin Lymphoma Hepatic Impairment Indolent Non-Hodgkin's Lymphoma Marginal Zone Lymphoma Rheumatoid Arthritis Asthma Hematologic Malignancies IPI-145 IPI-145 (duvelisib)

5Open jobs25Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Senior AccountantRemote (United States)Not statedOct 23, 2026
Associate Director, Regulatory OperationsRemote (United States)Not statedOct 16, 2026
Key Account Manager - FloridaRemote (United States)Not statedOct 16, 2026
Manager, Clinical SupplyRemote (United States)Not statedOct 16, 2026
Medical Science Liaison (MSL) - MidwestRemote (United States)Not statedOct 16, 2026

See all 5 jobs

Timeline

  1. Trial start Phase 1: A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides source ↗
  2. Trial start Phase 3: A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype source ↗
  3. Trial start Phase 1/Phase 2: A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer source ↗
  4. Trial start —: Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL source ↗
  5. Trial start 2: A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma source ↗
  6. Trial start Phase 2: A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) source ↗
  7. Trial start 2: Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma source ↗
  8. Trial start Phase 2: A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145) source ↗
  9. Trial start Phase 2: Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO) source ↗
  10. Trial start Phase 3: A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma source ↗
  11. Trial start Phase 1: Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY) source ↗
  12. Trial start Phase 1/Phase 2: A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO) source ↗
  13. Trial start Phase 1: Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145 source ↗
  14. Trial start Phase 3: Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma source ↗
  15. Trial start Phase 1: Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects source ↗
  16. Trial start 3: A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 source ↗
  17. Trial start 3: A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) source ↗
  18. Trial start 1: Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145 source ↗
  19. Trial start 1: Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam source ↗
  20. Trial start Phase 2: A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma source ↗
  21. Trial start Phase 2: A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone source ↗
  22. Trial start Phase 1: IPI-145 ADME and Absolute Bioavailability Study source ↗
  23. Trial start 2: A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects source ↗
  24. Trial start 1: A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies source ↗
  25. Trial start Phase 1: IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 25

RecordTitlePhaseStatusStartPrimary completion
NCT07714187A Study of Topical Duvelisib in Participants With Early-stage Mycosis FungoidesPhase 1Not yet recruiting2027-012028-10 (estimated)
NCT06522737A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) PhenotypePhase 3RecruitingMay 19, 20252028-02 (estimated)
NCT03372057A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)Phase 2CompletedFeb 22, 2018Dec 22, 2023 (actual)
NCT04038359A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma2CompletedSep 24, 2019Jul 24, 2023 (actual)
NCT02204982Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular LymphomaPhase 3Terminated2014-092016-12 (actual)
NCT02391545A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)Phase 1/Phase 2Terminated2014-12Jan 17, 2017 (actual)
NCT04193293A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck CancerPhase 1/Phase 2TerminatedJun 1, 2020Dec 10, 2020 (actual)
NCT02049515A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-073Completed2013-12Jun 12, 2020 (actual)
NCT02004522A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)3Completed2013-11May 19, 2017 (actual)
NCT02711852A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)Phase 2Completed2016-04May 4, 2020 (actual)
NCT01882803A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin LymphomaPhase 2CompletedJun 17, 2013Nov 18, 2020 (actual)
NCT03370185Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma2WithdrawnFeb 12, 20182020-06 (estimated)
NCT02292225Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)Phase 1Terminated2015-022016-11 (actual)
NCT02605694Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)Phase 2Withdrawn2015-122016-11 (actual)
NCT01549106IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction StudyPhase 1Completed2011-082012-02 (actual)
NCT02307461Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145Phase 1Completed2014-112015-08 (actual)
NCT04342117Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FLNot listedTerminatedApr 23, 2020Dec 31, 2020 (actual)
NCT02095587Duvelisib in Hepatically Impaired Subjects Compared to Healthy SubjectsPhase 1Completed2014-032014-07 (actual)
NCT02576275A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)Phase 3Withdrawn2015-122016-11 (actual)
NCT01851707A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate AlonePhase 2Completed2013-042014-12 (actual)
NCT01653756A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects2Completed2012-072014-08 (actual)
NCT01836861IPI-145 ADME and Absolute Bioavailability StudyPhase 1Completed2013-032013-04 (actual)
NCT01925911Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam1Completed2013-082013-09 (actual)
NCT01476657A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies1Terminated2011-102016-12 (actual)
NCT01947777Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-1451Completed2013-102013-11 (actual)

Open jobs 5

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Senior AccountantRemote (United States)Not statedOct 23, 2026Not stated
Associate Director, Regulatory OperationsRemote (United States)Not statedOct 16, 2026Senior
Key Account Manager - FloridaRemote (United States)Not statedOct 16, 2026Senior
Manager, Clinical SupplyRemote (United States)Not statedOct 16, 2026Mid
Medical Science Liaison (MSL) - MidwestRemote (United States)Not statedOct 16, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Secura Bio on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-04

Feedback